Is Bicuspid Aortic Valve Morphology Genetically Determined? A Family-Based Study.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 01 2022
Historique:
received: 07 07 2021
revised: 20 09 2021
accepted: 24 09 2021
pubmed: 21 11 2021
medline: 1 2 2022
entrez: 20 11 2021
Statut: ppublish

Résumé

Bicuspid aortic valve (BAV) is a common congenital heart disease, with a 10-fold higher prevalence in first-degree relatives. BAV has different phenotypes based on the morphology of cusp fusion. These phenotypes are associated with different clinical courses and prognoses. Currently, the determinants of the valve phenotype are unknown. In this study we evaluated the role of genetics using familial cohorts. Patients with BAV and their first-degree relatives were evaluated by echocardiography. The concordance in BAV phenotype between pairs of family members was calculated and compared with the concordance expected by chance. We then performed a systematic literature review to identify additional reports and calculated the overall concordance rate. During the study period, 70 cases from 31 families and 327 sporadic cases were identified. BAV was diagnosed in 14% of the screened relatives. The proportions of the morphologies identified was: 12.3% for type 0, 66.2% for type 1-LR, 15.4% for type 1-RN, 4.6% for type 1-NL, and 1.5% for type 2. For the assessment of morphologic concordance, we included 120 pairs of first-degree relatives with BAV from our original cohort and the literature review. Concordance was found only in 62% of the pairs which was not significantly higher than expected by chance. In conclusion, our finding demonstrates intrafamilial variability in BAV morphology, suggesting that morphology is determined by factors other than Mendelian genetics. As prognosis differs by morphology, our findings may suggest that clinical outcomes may vary even between first-degree relatives.

Identifiants

pubmed: 34799086
pii: S0002-9149(21)01005-5
doi: 10.1016/j.amjcard.2021.09.051
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

85-90

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosures All authors have no conflicts of interest to declare.

Auteurs

Idit Tessler (I)

Cardiology Department, Hadassah Medical Center, Jerusalem, Israel; Faculty of Medicine, the Hebrew University, Jerusalem, Israel. Electronic address: idit.tessler@gmail.com.

Guillaume Goudot (G)

Centre de Référence des Maladies Vasculaires Rares, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France; INSERM U970, PARCC, Université de Paris, Paris, France.

Juliette Albuisson (J)

Oncogenetics Laboratory, Centre George François Leclerc, Dijon, France; INSERM U970, PARCC, Université de Paris, Paris, France.

Noga Reshef (N)

Faculty of Medicine, the Hebrew University, Jerusalem, Israel.

Donna R Zwas (DR)

Cardiology Department, Hadassah Medical Center, Jerusalem, Israel; Faculty of Medicine, the Hebrew University, Jerusalem, Israel.

Shai Carmi (S)

Faculty of Medicine, the Hebrew University, Jerusalem, Israel.

Shoshana Shpitzen (S)

Cardiology Department, Hadassah Medical Center, Jerusalem, Israel; Faculty of Medicine, the Hebrew University, Jerusalem, Israel.

Galina Levin (G)

Cardiology Department, Hadassah Medical Center, Jerusalem, Israel.

Guy Kelman (G)

Cardiology Department, Hadassah Medical Center, Jerusalem, Israel.

Charles Cheng (C)

Centre de Référence des Maladies Vasculaires Rares, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France; INSERM U970, PARCC, Université de Paris, Paris, France.

Jean-Michaël Mazzella (JM)

Centre de Référence des Maladies Vasculaires Rares, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France; INSERM U970, PARCC, Université de Paris, Paris, France.

Yonatan Levin (Y)

Faculty of Medicine, the Hebrew University, Jerusalem, Israel.

Emmanuel Messas (E)

Centre de Référence des Maladies Vasculaires Rares, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France; INSERM U970, PARCC, Université de Paris, Paris, France.

Dan Gilon (D)

Cardiology Department, Hadassah Medical Center, Jerusalem, Israel; Faculty of Medicine, the Hebrew University, Jerusalem, Israel.

Ronen Durst (R)

Cardiology Department, Hadassah Medical Center, Jerusalem, Israel; Faculty of Medicine, the Hebrew University, Jerusalem, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH